strong sale growth consum mask resm
updat forecast estim jan
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jan
estim jan
price data jan
rate updat jan
currenc amount express
busi strategi outlook
methodolog valu compani
target larg potenti market opportun
nation heart blood lung institut estim
million american suffer sleep apnoea accord
fewer million diagnos
treat sleep apnoea year expand pool
diagnos treat sleep apnoea patient compani
target disord much gain
strategi involv increas awar disord
among physician gener popul compani
also make test sleep apnoea simpler home
test devic expand compani reach
patient unwil treat sleep lab
importantli aim introduc new devic
make patient comfort compliant
treatment provid compani stream
recur revenu
oan age popul coupl acceler obes
trend drive signific growth
steadi rate innov differenti
advantag histor support premium
omount evid clinic relev sleep
condit --
hypertens diabet -- increas demand
medic
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
develop manufactur distribut medic devic --
airflow gener mask -- treat breath disord also market
ventil product sleep apnoea remain compani primari
focu reach truli global distribut capabl
countri wholli own independ firm
increas proport manufactur capac singapor
still australia compani found
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
deliv solid
return long
innov
strong sale growth consum mask resm
retain usd fair valu estim narrow-moat-
rate follow releas second-quart
result decemb strong momentum mask sale
continu first quarter devic sale
particularli outsid america disappoint although
strong sale growth firm small software-as-a-
servic busi impress earn
moat underpin core sleep apnoea busi
enjoy switch cost command market
share littl chang australian dollar/u dollar
exchang rate fair valu estim australian cdi
remain aud fall around day
announc share trade
level consid fairli valu
core devic busi sluggish grow
prior correspond period constant-curr
basi canada latin america devic sale
growth off-set revenu declin rest
world market franc japan particularli
challeng follow digit health upgrad system
countri year-to-d sale growth segment
track unchang estim sale growth
fiscal longer term expect expand
devic busi high-single-digit compound annual
growth rate five year increas
share unpenetr henc grow market
mask busi increas revenu prior
correspond period constant-curr basi
favour shift product mix along manufactur
effici allow enjoy
expans gross margin first quarter
second quarter continu expect
mask grow low-double-digit compound-annual-growth-rate five
year fiscal
recent usd million acquisit matrixcar
usd million acquisit propel health push
net debt usd billion suspend
share buy-back programm accordingli nevertheless
level debt remain comfort forecast net debt/
ebitda fiscal fall back
fiscal level less next three year
board declar dividend usd cent per share
repres pay-out non-gaap ep usd
busi strategi outlook oct
remain one key leader sleep apnoea
treatment expect compani deliv solid return
long run underpin innov capabl
focus develop medic devic treat
sleep apnoea respiratori problem
educ caregiv therapi option firm
product portfolio consist airflow gener nasal
mask pillow introduc airflow need
prop open patient respiratori pathway sleep
tool help patient breath easier avoid
complic associ sleep apnoea includ
exhaust hypertens gener half
sale half sale
throughout europ japan
second mover sleep apnoea devic
initi forc play catch-up differenti
technic superior devic still aim maintain
technic edg serv well far patient
difficult time adjust sleep disrupt
advanc featur lead greater patient
comfort complianc turn lead brand loyalti
patient return sleep lab home
mask pillow -- highli profit recur revenu
stream help endear custom base
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fair valu estim stand usd per
share assign firm cost equiti littl
debt weight averag cost capit
five year fiscal expect key
demograph trend increas penetr
potenti patient pool greater awar
conveni test option drive compound annual
sale growth firm expect competit
environ five-year period limit scale
economi firm increas market spend
nevertheless forecast oper leverag drive
annual growth oper incom period
compani reach patient expect
educ home test initi
firm profit expand faster base forecast
better oper effici consid
rais fair valu estim usd per share
scenario assum sale increas
compound annual basi next five year effect
demand product deceler result
competit threat margin contract
consid lower fair valu estim usd
per share scenario assum sale increas
compound annual basi next five
assign narrow moat rate base
intang asset switch cost given strong track
record innov product introduct coupl
solid patent posit dug narrow econom
moat around busi develop
market capabl sleep apnoea devic new
product launch core sleep apnoea busi
face tough competit though particularli
philip formerli respiron respiron pioneer
industri possess admir market
distribut capabl accordingli product
becom synonym sleep apnoea treatment
 face difficult challeng tri
educ physician product set competitor
also shown willing compet price
blanket market free sampl past new
product launch continu impress
innov success combat price eros
prevent declin return capit
think prove abil develop new
sleep apnoea treatment expect
futur consid develop capabl
larg potenti patient pool remain
undiagnos untreat sleep apnoea market
look posit continu grow fast
clip fill gap exist therapeut option
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
grow portfolio respiratori product focus copd
neuromuscular diseas cardio-respiratori condit
underpin posit stanc compani strong
competit posit market educ
effort rais clinic profil sleep-disord
breath increas awar sleep apnoea
particular despit sign increas competit mask
low-tech end flow gener believ
integr product suit creat applic
switch cost clinician patient key aspect
latest product offer built-in wireless
connect togeth on-line data informat
manag tool clinician bode well patient
treatment efficaci
sleep apnoea
view moat trend stabl
philip effect duopoli domin
market sleep apnoea devic decad
absenc potenti disruptor horizon
see chang anytim soon prove
abil innov market healthcar stakehold
think firm remain leader market
forese futur expect momentum new
product develop maintain given on-going
research develop spend revenu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
target larg under-penetrated sleep-
disord breath market growth continu
strong trajectori patient incorpor
non-invasive treatment sleep
owith focu shift toward complianc rather
low-cost system thrive given
histori introduc innov product
oa signific boost at-hom sleep apnoea test
could open market patient object
costli uncomfort test sleep lab
abil sell product depend larg
willing third parti pay treatment
lower reimburs rate product
would hurt revenu margin potenti
research
develop unabl introduc new product
marketplac success sale margin
ocompetit sampl hurt growth recent
year practic return attract
sleep apnoea devic market could diminish
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
nearli usd million cash cash equival
june compar usd million total
debt remain excel financi health given
abil gener signific free cash flow expect
posit strengthen futur year
like medical-devic firm must innov
face signific price pressur compani may
abl stay head innov class futur
year would creat open competitor
compani also face foreign exchang risk substanti
develop manufactur oper remain
australia firm found
sale dispers throughout rest
world account half sale
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
farrel ceo sinc son founder
peter farrel compani execut chairman
strong free cash flow gener
intern fund growth mani year issu
fresh equiti employ rel littl debt return
invest capit consist well cost
capit upward trend recent year
major growth follow three major
research
develop maintain leadership posit
clinic trial demonstr medic benefit
treat condit distribut expertis reach
acquisit strategi buy rel small
firm complementari technolog intellectu
properti seen manag risk materi
amount capit acquisit found
value-destruct
repres date owner name posit common share held report holder issuer
capit research manag compani
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
strong sale growth consum mask resm
retain usd fair valu estim narrow-moat-
rate follow releas second-quart
result decemb strong momentum mask sale
continu first quarter devic sale
particularli outsid america disappoint although
strong sale growth firm small software-as-a-
servic busi impress earn
moat underpin core sleep apnoea busi
enjoy switch cost command market
share littl chang australian dollar/u dollar
exchang rate fair valu estim australian cdi
remain aud fall around day
announc share trade
level consid fairli valu
core devic busi sluggish grow
prior correspond period constant-curr
basi canada latin america devic sale
growth off-set revenu declin rest
world market franc japan particularli
challeng follow digit health upgrad system
countri year-to-d sale growth segment
track unchang estim sale growth
fiscal longer term expect expand
devic busi high-single-digit compound annual
growth rate five year increas
share unpenetr henc grow market
mask busi increas revenu prior
correspond period constant-curr basi
favour shift product mix along manufactur
effici allow enjoy
expans gross margin first quarter
second quarter continu expect
mask grow low-double-digit compound-annual-growth-rate five
year fiscal
recent usd million acquisit matrixcar
usd million acquisit propel health push
net debt usd billion suspend
share buy-back programm accordingli nevertheless
level debt remain comfort forecast net debt/
ebitda fiscal fall back
fiscal level less next three year
board declar dividend usd cent per share
repres pay-out non-gaap ep usd
resm strong sale momentum continu
fve unchang usd oct
retain fair valu estim usd narrow-
moat follow line result first
quarter fiscal fair valu estim per cdi
unchang aud base aud/usd exchang
rate current price share trade close
intrins assess
global sale grew first quarter track
full-year fiscal estim growth
driven mask devic america well
rest world
softwar servic saa segment
strongest growth rel small base
repres total revenu quarter saa
revenu boost aud million acquisit
healthcarefirst begin quarter organ
estim brightre busi grew
weakest categori mask sale europ asia
market grow constant currenc cc
term howev despit weak growth rate europ
manag maintain market share take
time penetr variou european countri new
devic mask introduc
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
quarter expect sale growth mask pick-up fiscal
sale devic grew strongli global averag
cc america devic revenu increas
quarter devic sale rest world grew
cc
group level gross margin slightli
unchang full-year estim
expect on-going manufactur procur effici
maintain gross profit margin current level offset
deflat averag sell price revenu growth
well ahead increas overhead cost higher
expens research develop result
margin increas basi point versu
non-gaap net incom increas usd
million board declar dividend usd cent per
share repres pay-out ratio non-gaap ep
usd
transfer coverag correct oct
correct per-shar earn dividend
estim australian cdi previou figur
inflat factor fair valu estim
rais fair valu estim usd
usd owe time valu money follow
transfer analyst coverag increas fair valu
estim australian cdi aud aud
princip due weaker australian dollar
exchang rate current around usd per aud
narrow moat stabl moat trend medium
uncertainti rate intact
sleep apnoea market effect duopoli
phillip formerli respiron togeth
command lion share market despit
catch first-mov respiron think
carv narrow econom moat technic
superior devic effect market support
firm intang asset firm market educ
effort rais clinic profil sleep-disord
breath increas awar sleep apnoea
particular moreov competit increas
mask low-tech end flow gener
integr product suit creat applic ecosystem
sleep apnoea therebi strengthen switch cost
clinician patient
product suit remain well-posit growth
peopl suffer sleep apnoea arent treat
henc signific portion firm potenti
market penetr increas increas awar
condit along home test becom
preval expect drive revenu compound-annual-growth-rate
firm last trade usd aud
respect share cdi close
transfer coverag oct
rais fair valu estim usd
usd owe time valu money follow
transfer analyst coverag increas fair valu
estim australian cdi aud aud
princip due weaker australian dollar
exchang rate current around usd per aud
narrow moat stabl moat trend medium
sleep apnoea market effect duopoli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
phillip formerli respiron togeth
command lion share market despit
catch first mover respiron think
carv narrow econom moat technic
superior devic effect market support
firm intang asset firm market educ
effort rais clinic profil sleep-disord
breath increas awar sleep apnoea
particular moreov competit increas
mask low-tech end flow gener
integr product suit creat applic ecosystem
sleep apnoea therebi strengthen switch cost
clinician patient
product suit remain well-posit growth
peopl suffer sleep apnoea arent treat
henc signific portion firm potenti
market penetr increas increas awar
condit along home test becom
preval expect drive revenu compound-annual-growth-rate
firm last trade usd aud
respect share cdi close
resm breez share appear fulli valu
narrow-moat deliv strong final quarter
solid growth front geographi despit fall
slightli short expect full year non-gaap
net incom usd million group revenu usd
billion respect year year
compar forecast usd million usd
billion nonetheless mask sale impress grow
around constant currenc fourth quarter
market rate full year unit state
rest world benefit continu strong
demand airfit full-fac mask airfit
nasal mask devic also perform strongli end year
year year constant currenc term
follow result rais fair valu estim
usd per share usd previous
adjust guidanc research develop
cost percentag group revenu time valu
money factor expect contribut
recent healthcarefirst acquisit fiscal forecast
specif reduc cost group
revenu previous revis fair valu
estim equat aud per cdi base
australian dollar/u dollar exchang rate
aud per cdi previous consid share
current level fulli valu
think cloud-connect suit product
remain well-posit compet develop market
given valu proposit patient clinician
clinic outcom reduc cost associ medic
condit healthcar payor expect
continu double-digit growth mask sale support
follow initi first resuppli program
home medic equip supplier essenti remind
end custom replac worn mask time basi
benefit
brightre patient
manag offer hospic homecar set
enhanc recent healthcarefirst bolt-on
use full-fac mask third favour
chang reimburs franc japan south
recent studi cite manag peg global
preval peopl mild moder sever sleep
apnoea around million estim
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
penetr around coupl grow
awar sleep apnoea associ medic
condit expect double-digit growth continu
remain comfort forecast global mask sale
grow five-year annual compound-annual-growth-rate compar
five-year sale compound-annual-growth-rate devic
unchang gross margin improv slightli
fiscal fiscal reflect
typic declin averag sell price off-set
manufactur procur effici
includ impact currenc movement remain
signific variabl top line cost line
balanc sheet remain solid usd million
cash hand well support on-going strong cash
flow oper impress cash flow
oper fiscal grew usd million
report debt/adjust ebitda period end
around time compar around time
fiscal follow sizabl usd million acquisit
brightre remain comfort
manag abil support dividend pay-out
ratio around also fund strateg
acquisit cloud-en softwar provid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end june
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end june
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
